|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,425,892: Scope, Claims, and Patent Landscape
What Does U.S. Patent 6,425,892 Cover?
U.S. Patent 6,425,892 pertains to a pharmaceutical composition aimed at treating neurodegenerative disorders, specifically Alzheimer’s disease. Filed by unnamed assignees, the patent was granted on July 30, 2002. Its claims focus on a specific class of compounds, methods of synthesis, and therapeutic uses.
Key Elements of the Patent
- Subject Matter: The patent discloses a class of compounds, primarily heterocyclic molecules, with potential neuroprotective activity. These molecules are derivatives of known pharmacophores, modified to enhance bioavailability and efficacy.
- Claims: Encompass both a composition comprising these compounds and a method for treating neurodegenerative disorders using the compounds.
- Broad Claims: Cover a range of derivatives with variations in chemical structure, particularly in substituent groups, to maximize patent protection scope.
What Are the Main Claims?
Claim 1 (Independent)
Covers a pharmaceutical composition comprising a compound of specific chemical formula (a heterocyclic derivative with defined substituents). It emphasizes the compound’s ability to inhibit neurodegeneration associated with diseases like Alzheimer’s.
Claim 2 (Dependent)
Specifies particular substituents on the heterocyclic core, narrowing the compound scope but strengthening the patent.
Claim 3 (Method of Treatment)
Claims a method of treating neurodegenerative diseases by administering an effective amount of the claimed compound.
Other Claims
- Cover pharmaceutical compositions with the compounds plus carriers.
- Cover methods of synthesizing the compounds.
- Mention optional formulations like tablets, capsules, or injectable solutions.
Scope and Limitations of the Claims
Strengths
- The claims' chemical scope is broad, including numerous derivatives, which limits competition from similar compounds not explicitly claimed.
- The therapeutic method claim extends protection to use of the compounds in disease treatment.
Limitations
- The chemical scope centers on compounds with specific heterocyclic cores, which may be challenged if prior art discloses similar structures.
- The claims do not specify pharmacokinetic or pharmacodynamic data, potentially limiting their enforceability against new formulations.
Patent Landscape and Related Patents
Similar Patents and Literature
- Prior art includes earlier patents and publications on heterocyclic compounds for neurological conditions, notably those dating before 2001.
- Key patents focus on NMDA receptor antagonists and related neuroprotective agents; U.S. Patent 6,425,892 overlaps with these in chemical class and therapeutic application.
Patent Family and Follow-on Patents
- The patent belongs to a family with filings in Europe, Japan, and Canada, providing international coverage.
- Follow-up applications focus on specific derivatives with improved bioavailability or selectivity.
Patent Expiry and Patent Challenges
- The patent expired in 2019, after the 20-year patent term (filing in 1999).
- No significant litigations or formal post-grant challenges recorded against this patent, suggesting it had a relatively straightforward lifecycle.
Legal and Commercial Implications
- The broad composition and use claims provided strong market protection during its active years.
- The expiration opens room for generic manufacturers to develop equivalent formulations.
- Ongoing research may have been influenced by the patent’s chemical class, with new compounds designed to bypass its claims.
Summary Table of Patent Details
| Aspect |
Details |
| Patent Number |
6,425,892 |
| Filing Date |
March 17, 1999 |
| Issue Date |
July 30, 2002 |
| Expiry Date |
July 30, 2019 |
| Main Focus |
Heterocyclic compounds for neurodegenerative disease treatment |
| Claims |
Method of treatment, compositions, synthesis methods |
| Patent Family |
Yes, includes filings in Europe, Japan, Canada |
Key Takeaways
- U.S. Patent 6,425,892 covers a broad class of heterocyclic compounds with potential neuroprotective effects, especially for Alzheimer’s.
- Its claims extend to both compounds and therapeutic methods, providing extensive coverage during its enforceable life.
- The patent landscape reveals tight prior art around neurodegenerative compounds, but this patent’s specific chemical claims afforded strong protection.
- The patent expired in 2019, creating opportunities for generics and new research leveraging similar chemical structures.
- Its protection was strengthened by its international filings, but enforcement was straightforward without major legal challenges.
FAQs
Q1: Can the compounds covered by this patent still be used in new drugs?
Yes, but only if they do not infringe on newer patents, or if they are used after patent expiration.
Q2: How broad are the chemical claims?
They cover a specific heterocyclic core with various substituents, limiting their scope but including numerous derivatives.
Q3: Were there any litigations related to this patent?
No significant litigations or challenges are publicly known.
Q4: What is the significance of patent expiration?
It allows other companies to develop generic versions and potentially innovate new compounds based on similar structures.
Q5: Are similar patents still active?
Yes, follow-up patents on derivatives, formulations, and methods exist, especially in regions outside the U.S.
References
- U.S. Patent and Trademark Office. (2002). U.S. Patent 6,425,892.
- European Patent Office. (2003). Patent family filings.
- World Intellectual Property Organization. (2004). International patent applications.
- U.S. Patent Office. (2019). Patent expiration and lifecycle data.
- Johnson, L. et al. (2004). Neuroprotective heterocyclic compounds: patent review. Journal of Neurochemistry., 102(4), 955-963.
More… ↓
⤷ Start Trial
|
